UK pharma giant GlaxoSmithKline (GSK; L) says that the European Commission has granted Marketing Authorisation to amend the licence for its cervical cancer vaccine, Cervarix. The approval is important, the company says, as it recognises the extent of cervical cancer protection demonstrated by Cervarix, which was not highlighted by the previous indication.
Friday, August 27, 2010
GlaxoSmithKline gets amended license for Cervarix
UK pharma giant GlaxoSmithKline (GSK; L) says that the European Commission has granted Marketing Authorisation to amend the licence for its cervical cancer vaccine, Cervarix. The approval is important, the company says, as it recognises the extent of cervical cancer protection demonstrated by Cervarix, which was not highlighted by the previous indication.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment